Summary
Chronic wounds in general and diabetic foot ulcers (DFU) in particular are a challenge to wound care specialists and health care systems. With 8.5% of the global population suffering from diabetes, diabetic foot disease results in costs of about €4.1bn yearly in Europe alone. Patients find their quality of life seriously affected and, in many cases, DFU leads to amputation. Standard treatment for chronic wounds today is moist wound healing with standard wound dressings. Lately, efforts have been made to introduce novel, advanced treatment options, such as skin grafts from mammalian tissue and growth factors. However, none of these has been able to provide solid evidence for clinical efficacy and cost-effectiveness, and they are not available through public health care systems in Europe.
Kerecis (Iceland), the coordinator of the Kerefish project, has developed KerecisTM Omega3 Wound, a novel skin substitute derived from North Atlantic cod skin. The unique structure of the grafts and their high content of Omega 3 fatty acids promote wound healing, even in severe DFU cases. KerecisTM Omega3 Wound has received the CE mark and FDA approval. However, as it is currently not reimbursed by public health systems in Europe, it is not yet available for the European population.
Kerecis has teamed up with CERITD (France), an association for diabetes prevention and treatment and Endospin (Italy), a distributor of wound care products with experience in clinical trial sponsoring, to carry out large-scale clinical trials in 4 European countries and prepare the path to reimbursement and to the European health care market for this disruptive product, which will improve patients quality of life and help solve one of the pressing health problems of today’s societies.
The Kerefish project will accumulate €70M of revenues and €18M of EBITDA in the first 5 years of commercialization.
Kerecis (Iceland), the coordinator of the Kerefish project, has developed KerecisTM Omega3 Wound, a novel skin substitute derived from North Atlantic cod skin. The unique structure of the grafts and their high content of Omega 3 fatty acids promote wound healing, even in severe DFU cases. KerecisTM Omega3 Wound has received the CE mark and FDA approval. However, as it is currently not reimbursed by public health systems in Europe, it is not yet available for the European population.
Kerecis has teamed up with CERITD (France), an association for diabetes prevention and treatment and Endospin (Italy), a distributor of wound care products with experience in clinical trial sponsoring, to carry out large-scale clinical trials in 4 European countries and prepare the path to reimbursement and to the European health care market for this disruptive product, which will improve patients quality of life and help solve one of the pressing health problems of today’s societies.
The Kerefish project will accumulate €70M of revenues and €18M of EBITDA in the first 5 years of commercialization.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/878896 |
| Start date: | 01-11-2019 |
| End date: | 31-08-2023 |
| Total budget - Public funding: | 3 741 044,00 Euro - 2 995 417,00 Euro |
Cordis data
Original description
Chronic wounds in general and diabetic foot ulcers (DFU) in particular are a challenge to wound care specialists and health care systems. With 8.5% of the global population suffering from diabetes, diabetic foot disease results in costs of about €4.1bn yearly in Europe alone. Patients find their quality of life seriously affected and, in many cases, DFU leads to amputation. Standard treatment for chronic wounds today is moist wound healing with standard wound dressings. Lately, efforts have been made to introduce novel, advanced treatment options, such as skin grafts from mammalian tissue and growth factors. However, none of these has been able to provide solid evidence for clinical efficacy and cost-effectiveness, and they are not available through public health care systems in Europe.Kerecis (Iceland), the coordinator of the Kerefish project, has developed KerecisTM Omega3 Wound, a novel skin substitute derived from North Atlantic cod skin. The unique structure of the grafts and their high content of Omega 3 fatty acids promote wound healing, even in severe DFU cases. KerecisTM Omega3 Wound has received the CE mark and FDA approval. However, as it is currently not reimbursed by public health systems in Europe, it is not yet available for the European population.
Kerecis has teamed up with CERITD (France), an association for diabetes prevention and treatment and Endospin (Italy), a distributor of wound care products with experience in clinical trial sponsoring, to carry out large-scale clinical trials in 4 European countries and prepare the path to reimbursement and to the European health care market for this disruptive product, which will improve patients quality of life and help solve one of the pressing health problems of today’s societies.
The Kerefish project will accumulate €70M of revenues and €18M of EBITDA in the first 5 years of commercialization.
Status
SIGNEDCall topic
EIC-FTI-2018-2020Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
